Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases

被引：0
|
作者：
Maria Fasshauer
Michael Borte
Michaela Bitzenhofer
Christine Pausch
David Pittrow
Michelle Park
André Gladiator
Peter Jandus
机构：
[1] Hospital St. Georg,Hospital for Children and Adolescents
[2] Academic Teaching Hospital of the University of Leipzig,ImmunoDeficiencyCenter Leipzig (IDCL)
[3] Hospital St. Georg,Division of Allergology and Clinical Immunology, Department of Pneumology
[4] Academic Teaching Hospital of the University of Leipzig,Institute for Clinical Pharmacology
[5] University Hospital Berne (Inselspital Bern),Division of Clinical Immunology and Allergy, Department of Medicine
[6] GWT-TUD GmbH,undefined
[7] Innovation Centre Real World Evidence,undefined
[8] Technical University,undefined
[9] Takeda Development Center Americas,undefined
[10] Inc.,undefined
[11] Takeda Pharmaceuticals International AG,undefined
[12] University Hospital and Medical Faculty,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Antibody deficiency syndromes; Ig20Gly; Immunoglobulin replacement therapy; Inborn errors of immunity; Observational; Primary immunodeficiency diseases; SCIG; Subcutaneous immunoglobulin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5168 / 5187
页数：19
相关论文
共 50 条
  • [1] Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases
    Fasshauer, Maria
    Borte, Michael
    Bitzenhofer, Michaela
    Pausch, Christine
    Pittrow, David
    Park, Michelle
    Gladiator, Andre
    Jandus, Peter
    ADVANCES IN THERAPY, 2023, 40 (12) : 5168 - 5187
  • [2] FROM CLINICAL TRIAL TO REAL-WORLD USE: SUBCUTANEOUS IMMUNOGLOBULIN (SCIG) 20% INFUSION IN PRIMARY IMMUNODEFICIENCY DISORDERS
    Carne, E.
    Panahloo, Z.
    Barber, S.
    Morris, K.
    El-Shanawany, T.
    Jolles, S.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 167 - 167
  • [3] Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents
    Suez, Daniel
    Krivan, Gergely
    Jolles, Stephen
    Stein, Mark
    Gupta, Sudhir
    Paris, Kenneth
    van Hagen, P. Martin
    Brodszki, Nicholas
    Engl, Werner
    Leibl, Heinz
    McCoy, Barbara
    Yel, Leman
    IMMUNOTHERAPY, 2019, 11 (12) : 1057 - 1065
  • [4] Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases
    Hirokazu Kanegane
    Kohsuke Imai
    Masafumi Yamada
    Hidetoshi Takada
    Tadashi Ariga
    Martin Bexon
    Mikhail Rojavin
    Wilson Hu
    Midori Kobayashi
    John-Philip Lawo
    Shigeaki Nonoyama
    Toshiro Hara
    Toshio Miyawaki
    Journal of Clinical Immunology, 2014, 34 : 204 - 211
  • [5] Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases
    Kanegane, Hirokazu
    Imai, Kohsuke
    Yamada, Masafumi
    Takada, Hidetoshi
    Ariga, Tadashi
    Bexon, Martin
    Rojavin, Mikhail
    Hu, Wilson
    Kobayashi, Midori
    Lawo, John-Philip
    Nonoyama, Shigeaki
    Hara, Toshiro
    Miyawaki, Toshio
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (02) : 204 - 211
  • [6] Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment
    Rosenbach, Kevin
    Park, Michelle
    Sanchirico, Marie
    Nwose, Oliseyenum
    Paris, Kenneth
    JOURNAL OF CLINICAL IMMUNOLOGY, 2023, 43 (05) : 912 - 920
  • [7] Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment
    Kevin Rosenbach
    Michelle Park
    Marie Sanchirico
    Oliseyenum Nwose
    Kenneth Paris
    Journal of Clinical Immunology, 2023, 43 (5) : 912 - 920
  • [8] 20% subcutaneous immunoglobulin for patients with primary immunodeficiency diseases: A systematic review
    Song, Jie
    Zhang, Lingli
    Li, Youping
    Quan, Shuyan
    Liang, Yi
    Zeng, Linan
    Liu, Yi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2015, 25 (02) : 457 - 464
  • [9] Real-World Safety and Tolerability of Facilitated Subcutaneous Immunoglobulin in Pediatric Patients with Primary Immunodeficiency Diseases: Interim Analysis from a Post-authorization Study in Europe
    Ciznar, Peter
    Roderick, Marion
    Schneiderova, Helena
    Jesenak, Milos
    Krivan, Gergely
    Brodszki, Nicholas
    Jolles, Stephen
    Fielhauer, Katharina
    Saeed-Khawaja, Shumyla
    McCoy, Barbara
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2021, 41 (SUPPL 1) : S97 - S98
  • [10] Real-world use of facilitated subcutaneous immunoglobulin in patients with secondary immunodeficiency diseases (SID): interim results from the FIGARO study
    Dimou, M.
    Huscher, D.
    Hermann, C.
    Pittrow, D.
    Speletas, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 184 - 184
12345